myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Status Recruiting

Clinical Trial Summary

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages III-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

Clinical Trial Description

Objectives: Primary Objective: To determine if HFNT delivered by myAirvo 3 increases the time to first moderate exacerbation orsevere exacerbation or all-cause mortality in patients with moderate to very severe COPD Secondary Objectives: To determine if HFNT delivered by myAirvo 3 1. increases the time to first severe exacerbation 2. increases the time to first exacerbation (moderate or severe) 3. reduces severe exacerbation frequency 4. reduces moderate and severe exacerbation frequency 5. reduces hospitalization duration 6. improves quality of life 7. reduces dyspnea 8. reduces PCO2 9. is safe and well tolerated 10. determine if any of the objectives are related to duration of daily HFNT use 11. Assess cost effectiveness of HFNT use Exploratory objectives: Develop objective definitions of exacerbations of differing levels of severity based on myAirvo 3 device or electronic diary collected measures of heart rate, respiratory rate, oxygen saturation, and dyspnea measured by modified visual analog score. Endpoints: Primary Endpoint: The time to first moderate or severe exacerbation or all-cause mortality. Primary Safety Endpoint: All data on adverse events, including reported to be not, possibly, probably, or definitely related to the use of myAirvo 3 device. Secondary Endpoints: - Rate of severe exacerbation, rate of moderate and severe exacerbations, - Time to moderate exacerbation, time to severe exacerbation, time to moderate or severe exacerbation - Hospitalization durations, from per visit data - Quality of life by St George's Respiratory Questionnaire and SF-12 - Dyspnea, calculated mMRC and TDI over time - Hours of daily HFNT use - Impact of hours of daily HFNT use on any outcome - PCO2 - Assess patient phenotype most likely to benefit from HFNT. - Assess cost effectiveness of HFNT use Exploratory endpoints: - Development of objective definitions of exacerbations of differing levels of severity based on myAirvo 3 device or electronic diary collected measures of heart rate, respiratory rate, oxygen saturation, and dyspnea measured by modified visual analog score. - HFNT settings (flow rate and temperature) ;

Study Design

Related Conditions & MeSH terms

COPD

Clinical Trial Details

NCT number	NCT05204888
Study type	Interventional
Source	Temple University
Contact	Gerard Criner, MD
Phone	215-707-8113
Email	[email protected]
Status	Recruiting
Phase	N/A
Start date	February 2, 2022
Completion date	March 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03927820` - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
Completed	`NCT04043728` - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study	N/A
Completed	`NCT04105075` - COPD in Obese Patients
Recruiting	`NCT04075331` - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial	Phase 2/Phase 3
Terminated	`NCT03640260` - Respiratory Regulation With Biofeedback in COPD	N/A
Recruiting	`NCT04872309` - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting	`NCT05145894` - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Not yet recruiting	`NCT04210050` - Sleep Ventilation for Patients With Advanced Hypercapnic COPD	N/A
Terminated	`NCT03284203` - Feasibility of SpiroPD	N/A
Recruiting	`NCT04868357` - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program	N/A
Completed	`NCT04119856` - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD	N/A
Recruiting	`NCT04485741` - Strados System at Center of Excellence
Completed	`NCT03626519` - Effects of Menthol on Dyspnoea in COPD Patients	N/A
Recruiting	`NCT04860375` - Multidisciplinary Management of Severe COPD	N/A
Active, not recruiting	`NCT05311657` - Oral Health and Severe COPD
Not yet recruiting	`NCT04260243` - Myofascial Release in Patients With Chronic Obstructive Pulmonary Disease	N/A
Not yet recruiting	`NCT05444062` - Quebec Lung Cancer Screening PLUS Trial	N/A
Not yet recruiting	`NCT05495698` - Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease	N/A
Not yet recruiting	`NCT05362526` - High Flow vs Conventional Oxygen in Head and Neck Surgery	N/A
Not yet recruiting	`NCT03278795` - VSV Versus PSV as a Weaning Mode of Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients	N/A